<DOC>
	<DOCNO>NCT00197041</DOCNO>
	<brief_summary>Malaria important cause death serious illness among Mozambican child . Although risk malaria reduce drug impregnate bed net , would helpful child could protect malaria vaccine . GSK Biologicals develop partnership Malaria Vaccine Initiative PATH candidate malaria vaccine RTS , S/AS02 routine immunization infant child live malaria endemic area . The vaccine would offer protection malaria disease due parasite Plasmodium falciparum also would provide protection infection hepatitis B virus . Previous study show candidate malaria vaccine RTS , S/AS02 safe administer adult child age 1-11 year . However , assess vaccine could provide protection malaria child , study undertaken .</brief_summary>
	<brief_title>A Study Evaluate Safety , Immunogenicity Efficacy GlaxoSmithKline ( GSK ) Biologicals ' Candidate Malaria Vaccine RTS , S/AS02A , When Administered Children Aged 1 4 Years Living Malaria-endemic Region Mozambique .</brief_title>
	<detailed_description>In study , participate child either receive either 3 dos new malaria vaccine control vaccine select benefit child prevent important childhood disease . The control vaccines include follow : - If child 24 month old , he/she may receive 3 dos vaccine , call Engerix-B™ , protect hepatitis B . - If child le 24 month , he/she may receive : two dos vaccine call Prevnar® one dose vaccine call Hiberix™ . Prevnar® prevent pneumonia meningitis cause Streptococcus pneumoniae bacteria . Hiberix™ prevents severe infection pneumonia meningitis cause Haemophilus influenzae type b bacteria ( Hib ) . All child monitor development malaria disease 18-month period extend third vaccination . All participant also monitor vaccine safety first vaccination study close .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Healthy male female child , 1 4 year age time first vaccination ( include 5th birthday ) . Written/thumbprinted witness informed consent obtain parent legal guardian . Major congenital defect serious chronic illness . History allergic reaction vaccination component Hiberix™ , Prevnar® EngerixB™ vaccine . Chronic administration ( defined 14 day ) immunosuppressant immune modify drug within six month prior first vaccine dose . Previous vaccination experimental vaccine hepatitis B vaccine child equal 18 month age . Simultaneous participation clinical trial . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration vaccine foreseen study protocol within 30 day first dose vaccine . An exception , receipt EPI license vaccine . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>